|Bid||131.3200 x 100|
|Ask||131.3500 x 300|
|Day's Range||130.5701 - 131.7866|
|52 Week Range||119.2500 - 148.3200|
|PE Ratio (TTM)||279.53|
|Forward Dividend & Yield||3.36 (2.52%)|
|1y Target Est||N/A|
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform, with most US healthcare companies reporting one-time financial effects on their balance sheets.
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Something odd has been happening to short-term bank bonds. So far this month, spreads on banks' two-year bonds have widened by more than 15 basis points, according to Bank of America Merrill Lynch. For ...
Johnson & Johnson is seeking buyers for its sterilization products division, people familiar with the matter said, as the health-care conglomerate continues to sell off non-core assets.
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
If there were a healthcare Olympics, this company would bring home the gold this year because of its rock-solid financials.
NEW YORK (AP) — Stocks closed out their strongest week in five years Friday and have now recovered more than half of the losses they suffered in a plunge at the beginning of the month.
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.
Novartis: What Are the Major Growth Drivers for 2018? On September 7, 2017, Novartis (NVS) announced positive results from its pivotal Phase 2 study, which highlighted the consistent efficacy demonstrated by Aimovig. This efficacy was measured through changes in monthly migraine days in chronic migraine patients who failed to respond to previous preventive therapies.
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
On February 15, 2018, Teva Pharmaceutical (TEVA) stock registered a rise of ~10.5% in pre-market trading on the disclosure of Berkshire Hathaway’s (BRK) investment of $358 million in the stock at the end of 4Q17. Berkshire Hathaway’s investment in Teva bodes well for Teva investors. Given that Berkshire Hathaway’s investments are based on founder Warren Buffet’s value investing strategy, Teva is now seen as a fundamental value investment.